Cytokinetics (NASDAQ:CYTK) quickly rose 7.5% amid some renewed takeover speculation. There's some speculation that the company has had some fresh bid interest, according to traders, who cited a ...

A rumor regarding Cytokinetics (CYTK) was highlighted in an alert sent to subscribers of Ben Harrington’s takeover-focused Betaville blog, ...

Fintel reports that on February 13, 2025, Morgan Stanley upgraded their outlook for Cytokinetics (NasdaqGS:CYTK) from ...